What's Happening?
Precision BioSciences, a clinical-stage gene editing company, has presented new preclinical data at the American Society of Gene & Cell Therapy 2026 Annual Meeting. The data highlights the efficacy of their
PBGENE-DMD program, which utilizes the ARCUS® platform to treat Duchenne Muscular Dystrophy (DMD). The study demonstrated that early intervention in juvenile mice led to significantly higher dystrophin protein restoration in skeletal and respiratory muscles compared to later intervention. This suggests that treating DMD patients as young as two years old could yield better outcomes. The PBGENE-DMD program aims to provide a durable treatment by excising exons 45-55 of the dystrophin gene, potentially benefiting about 60% of DMD patients.
Why It's Important?
The findings from Precision BioSciences' study are significant as they offer a potential breakthrough in treating Duchenne Muscular Dystrophy, a severe genetic disorder with limited treatment options. By targeting younger patients, the PBGENE-DMD program could improve long-term outcomes and quality of life for those affected. The approach of gene correction rather than synthetic transgene delivery may provide a more durable solution, avoiding issues like the AAV dilution effect seen in other treatments. This development could influence future gene therapy strategies and regulatory approvals, potentially setting a new standard for DMD treatment.
What's Next?
Precision BioSciences plans to continue evaluating PBGENE-DMD in clinical trials, specifically targeting young DMD patients. The ongoing Phase 1/2 FUNCTION-DMD trial will assess the safety and efficacy of the treatment in boys aged 2 to 7. The program has already received Orphan Drug and Fast Track designations from the FDA, which could expedite its path to market. As the trial progresses, the company will monitor for any regulatory updates and potential collaborations to enhance the program's reach and impact.
